Remember you can't do anything with this until, well never. Your doctor will need to prescribe this and that won't occur since your doctor won't contact researchers to get research done and a protocol written. You will need this because of side effects from your stroke. This from Nov. 2015 just shows you how incompetent your doctor is in not following up any interesting research.
You will need this.
Your chances of getting dementia.
2. Then this study came out and seems to have a range from 17-66%. December 2013.
Salk Institute's J147 is a derivative of turmeric, a spice used in
curry. Learn how it fights memory deficits and has a host of unexpected
anti-aging effects in the lab.
Salk Institute researchers have found that J147, which is an
experimental drug candidate aimed at combating Alzheimer's disease, has a
host of unexpected anti-aging effects in animals.
J147, Alzheimer's and Old Age
The Salk team expanded upon their previous development of the drug
candidate they labeled J147. It is a derivative of the common spice,
turmeric, and takes a different tack by targeting
Alzheimer's major risk factor -- old age.
In the new work, the team showed that the drug candidate worked well in
a mouse model of aging not typically used in Alzheimer's research. When
these mice were treated with J147, they had better memory and
cognition, healthier blood vessels in the brain and other improved
physiological features, as detailed in the journal Aging.
Fighting Alzheimer's By Fighting Aging
"Initially, the impetus
was to test this drug in a novel animal model that was more similar to
99 percent of Alzheimer's cases," says Antonio Currais, the lead author
and a member of Professor David Schubert's Cellular Neurobiology
Laboratory at Salk. "We did not predict we'd see this sort of anti-aging
effect, but J147 made old mice look like they were young, based upon a
number of physiological parameters."
Alzheimer's disease is a progressive brain disorder, recently ranked as
the third leading cause of death in the United States and affecting more
than five million Americans. It is also the most common cause of
dementia in older adults, according to the National Institutes of
Health.
"While most drugs developed in the past 20 years target the amyloid
plaque deposits in the brain (which are a hallmark of the disease), none
have proven effective in the clinic," says Schubert, senior author of
the study.
Expanding the Fight to More Common Dementias
Several years ago, Schubert and his colleagues began to approach the
treatment of the disease from a new angle. Rather than target amyloid,
the lab decided to zero in on the major risk factor for the disease--old
age. Using cell-based screens against old age-associated brain
toxicities, they synthesized J147.
Previously, the team found that J147 could prevent and even reverse
memory loss and Alzheimer's pathology in mice that have a version of the
inherited form of Alzheimer's, the most commonly used mouse model.
However, this form of the disease comprises only about 1 percent of
Alzheimer's cases. For everyone else, old age is the primary risk
factor, says Schubert. The team wanted to explore the effects of the
drug candidate on a breed of mice that age rapidly and experience a
version of dementia that more closely resembles the age-related human
disorder.
Young Mice, Old Mice and J147-fed Mice
In this latest work, the researchers used a comprehensive set of assays
to measure the expression of all genes in the brain, as well as over 500
small molecules involved with metabolism in the brains and blood of
three groups of the rapidly aging mice. The three groups of rapidly
aging mice included one set that was young, one set that was old and one
set that was old but fed J147 as they aged.
7 Benefits
The old mice fed J147 saw the following benefits:
- They performed better on memory and other tests for cognition
- They displayed more robust motor movements.
- They had fewer pathological signs of Alzheimer's in their brains.
- J147 prevented the leakage of blood from the microvessels in the
brains of old mice. "Damaged blood vessels are a common feature of aging
in general, and in Alzheimer's, it is frequently much worse," says
Currais.
Importantly, because of the large amount of data collected on the
three groups of mice, it was possible to demonstrate that many aspects
of gene expression and metabolism in the old mice fed J147 were very
similar to those of the young animals. These included:
- markers for increased energy metabolism,
- reduced brain inflammation and
- reduced levels of oxidized fatty acids in the brain.
Human Clinical Trials
Currais and Schubert note that while these studies represent a new and
exciting approach to Alzheimer's drug discovery and animal testing in
the context of aging, the only way to demonstrate the clinical relevance
of the work is to move J147 into human clinical trials for Alzheimer's
disease.
"If proven safe and effective for Alzheimer's, the apparent
anti-aging effect of J147 would be a welcome benefit," adds Schubert.
The team aims to begin human trials next year.
Related Article:
MORE INFORMATION:
- Other authors on the paper include Oswald Quehenberger of the
University of California, San Diego; and Joshua Goldberg, Catherine
Farrokhi, Max Chang, Marguerite Prior, Richard Dargusch, Daniel
Daugherty and Pamela Maher of the Salk Institute.
- This study was supported by the Salk Institute Pioneer Fund
Postdoctoral Scholar Award and the Salk Nomis Fellowship Award,
fellowships from the Hewitt Foundation and Bundy Foundation, and grants
from the Burns Foundation and NIH.
SOURCE:
